# Pemphigus Vulgaris

Confirm pemphigus vulgaris with lesion-directed immunopathology, distinguish it from other blistering disorders and paraneoplastic disease, then use severity and mucosal risk to select systemic corticosteroids, rituximab-based therapy, and steroid-sparing maintenance.

**Clinical question:** How should physicians confirm, risk-stratify, and treat pemphigus vulgaris while limiting corticosteroid toxicity and relapse?

Updated: 2026-09-15T23:42:41.690112+00:00

## What matters in practice
- Establish the diagnosis with compatible erosive or blistering disease plus lesion-directed histopathology and immunopathologic testing; PV is an intraepidermal autoimmune blistering disorder. [1][11][24]
- For moderate-to-severe pemphigus, intravenous CD20-directed therapy is a first-line option and provides a corticosteroid-sparing effect. [4][11]
- Systemic corticosteroid regimens cited in pemphigus guidance use initial doses of 1.0-1.5 mg/kg/day; tapering should follow disease control rather than a fixed calendar schedule. [16][11]
- Escalate evaluation when mucosal disease compromises oral intake or when laryngeal involvement is suspected, because deep laryngeal disease requires targeted assessment. [8]

## Confirm pemphigus vulgaris before prolonged immunosuppression

Use tissue and immunopathology to separate PV from clinically similar blistering diseases.

Obtain a biopsy from an active lesion for routine histopathology and a separate perilesional specimen for immunopathologic assessment when PV is suspected clinically. Pemphigus disorders are defined by intraepidermal split formation, whereas other autoimmune bullous diseases blister at the basement-membrane zone; this distinction redirects both serologic interpretation and treatment planning. [11][24]

Do not treat persistent oral erosions or erosive skin disease as PV on morphology alone. The diagnostic branch includes PV, pemphigus foliaceus, drug-induced pemphigus, paraneoplastic pemphigus, and non-pemphigus autoimmune blistering disease; the level of split formation and autoantibody pattern determine the specific diagnosis. [11][24]

If erosions are extensive, involve multiple mucosal sites, or precede systemic treatment, document baseline extent and functional consequences, particularly oral intake. Clinical assessment remains central because pemphigus diagnosis is based on the observed pattern of erosions, epidermal loss, and blisters in conjunction with confirmatory testing. [1]
- Biopsy an active lesion for routine histology to establish the level of epidermal separation. [24]
- Submit perilesional tissue for immunopathologic testing rather than relying only on a lesional ulcer base. [11]
- Reconsider paraneoplastic pemphigus or another autoimmune blistering disease when clinical distribution, pathology, or immunopathology does not fit conventional PV. [11][24]

*Diagnostic branches in patients presenting with suspected pemphigus-spectrum disease. [11][24]*

| Clinical-pathologic branch | Key discriminator | Next action |
| --- | --- | --- |
| Pemphigus vulgaris | Intraepidermal split formation with a compatible mucocutaneous erosive or blistering phenotype. [24] | Confirm immunopathologically and assess extent of mucosal and cutaneous disease before selecting systemic therapy. [1][11] |
| Pemphigus foliaceus | A pemphigus variant distinguished by its clinical and immunopathologic pattern. [11][24] | Classify as PF rather than PV because phenotype and disease distribution affect management planning. [11] |
| Basement-membrane-zone autoimmune blistering disease | Blistering occurs at the basement membrane zone rather than within the epidermis. [24] | Redirect diagnostic testing and avoid assuming PV based on erosions alone. [24] |
| Paraneoplastic or drug-induced pemphigus | Recognized pemphigus variants requiring etiologic classification. [11][24] | Investigate the relevant precipitating or associated condition while confirming the immunobullous diagnosis. [11][24] |

## Identify mucosal and airway disease that changes urgency

Mucosal burden determines immediate supportive needs and the threshold for specialty assessment.

Assess oral disease at presentation for painful erosions that limit hydration, nutrition, medication administration, or oral hygiene. Mucocutaneous PV requires treatment planning that addresses both mucosal and skin activity rather than judging severity from cutaneous blisters alone. [13][18]

Ask specifically about dysphonia, odynophagia, dysphagia, throat pain, cough, or dyspnea. Laryngeal involvement occurs in PV, and a clinical prediction model has been developed for deep laryngeal involvement; concerning upper-airway symptoms should prompt direct laryngeal assessment rather than observation alone. [8]

When oral intake is impaired, address hydration and nutritional support concurrently with disease-directed immunosuppression. Referral to clinicians experienced in mucosal autoimmune blistering disease is particularly important when oral, pharyngeal, esophageal, or laryngeal involvement is suspected. [13][8]
- Same-day escalation: dyspnea, stridor, rapidly progressive voice change, or inability to maintain hydration because of mucosal erosions. [8][13]
- Document mucosal sites separately from skin involvement to avoid underestimating predominantly mucosal PV. [13][18]
- Use laryngeal evaluation for concerning symptoms because deep laryngeal involvement cannot be reliably inferred from oral examination alone. [8]

*Mucosal findings that should alter the immediate next step. [8][13][18]*

| Finding | Clinical implication | Next step |
| --- | --- | --- |
| Painful oral erosions with reduced intake | Mucocutaneous PV can create immediate hydration and nutrition barriers. [13][18] | Treat disease activity and provide hydration and nutritional support while assessing the need for more intensive care. [13] |
| Dysphonia, odynophagia, dysphagia, throat pain, cough, or dyspnea | Potential laryngeal involvement. [8] | Arrange targeted laryngeal assessment; do not rely on oral examination alone. [8] |
| Multisite mucosal involvement | May indicate clinically consequential mucocutaneous disease despite limited skin findings. [13][18] | Use mucosal burden when determining systemic treatment intensity and follow-up needs. [13][11] |

## Select initial systemic treatment by severity and steroid-sparing need

Moderate-to-severe PV generally warrants systemic therapy from the outset.

For moderate-to-severe PV, consider rituximab as a first-line systemic option, combined with the corticosteroid strategy needed for disease control. International expert consensus includes intravenous CD20 inhibitors as first-line therapy for moderate-to-severe pemphigus, and rituximab has demonstrated a steroid-sparing effect in PV. [11][4]

Systemic corticosteroids remain an induction option; cited guideline dosing is 1.0-1.5 mg/kg/day of systemic corticosteroid therapy for initial PV/PF treatment. [16] A separate oral PV treatment protocol used prednisolone 1 mg/kg/day initially, with reassessment after 4-6 weeks. [18] Use the lowest regimen that achieves control and taper only after disease control, because consensus guidance addresses maintenance and tapering in remission rather than endorsing an arbitrary early taper. [11]

For patients in whom rituximab is unavailable, contraindicated, or insufficiently effective, conventional immunosuppressive adjuncts are used as steroid-sparing therapy. Mycophenolate mofetil has been used at 2-3 g/day in two divided doses in PV; comparative discussions note a tradeoff between lower hepatotoxicity and differing corticosteroid-sparing performance versus azathioprine. [14]
- Moderate-to-severe PV: discuss rituximab early rather than reserving it solely for refractory disease. [11][4]
- Initial systemic corticosteroid dose cited in guidance: 1.0-1.5 mg/kg/day. [16]
- Oral-PV protocol example: prednisolone 1 mg/kg/day, reassessed at 4-6 weeks. [18]
- Mycophenolate mofetil dosing reported for PV: 2-3 g/day divided twice daily. [14]

### When to use rituximab beyond initial therapy

Rituximab also has evidence in refractory PV. A study of refractory disease reported effectiveness of rituximab combined with intravenous immune globulin, while earlier severe-pemphigus trial data support effectiveness of a single rituximab cycle but emphasize potential severe adverse effects. [5][7]
- Refractory PV: consider rituximab-based escalation; IVIG has been used in combination for refractory disease. [5]
- Balance expected disease control against rituximab's potential for severe adverse effects. [7]

*Systemic treatment options supported in the cited PV literature. [4][5][7][11][14][16][18]*

| Clinical situation | Treatment approach | Decision point |
| --- | --- | --- |
| Moderate-to-severe PV | Rituximab is a first-line intravenous CD20-inhibitor option, with systemic corticosteroids used for disease control. [11][4] | Prioritize steroid-sparing benefit when prolonged high-dose corticosteroid exposure is likely. [4][11] |
| Initial corticosteroid induction | Systemic corticosteroid 1.0-1.5 mg/kg/day in guideline-based initial treatment; one oral-PV protocol used prednisolone 1 mg/kg/day. [16][18] | Reassess activity before tapering; the oral-PV protocol reassessed at 4-6 weeks. [18][11] |
| Need for a conventional steroid-sparing adjunct | Mycophenolate mofetil 2-3 g/day in two divided doses has been reported for PV. [14] | Weigh hepatotoxicity and corticosteroid-sparing tradeoffs relative to azathioprine. [14] |
| Refractory PV | Rituximab plus IVIG has shown effectiveness in refractory PV. [5] | Escalate after confirming active PV and reassessing whether infection, treatment toxicity, or an alternate diagnosis explains apparent failure. [5][11] |

## Monitor for disease control, remission, and relapse rather than treating by time alone

Follow clinical activity closely during corticosteroid reduction and after B-cell-directed therapy.

At each follow-up, determine whether new erosions or blisters are appearing, whether prior lesions are healing, and whether mucosal symptoms are improving enough to restore oral intake and function. Consensus recommendations specifically address maintenance therapy and medication tapering in remission, making clinical disease control the central trigger for de-escalation. [11]

Counsel patients receiving rituximab that relapse remains clinically relevant after initial response. Reported 12-month relapse-free survival rates in PV rituximab studies ranged from 40% to 80%, supporting planned surveillance rather than assuming a single infusion cycle produces durable remission in every patient. [9]

In one newly diagnosed pemphigus cohort, rituximab was administered as 1,000 mg intravenously on days 0 and 14, followed by a 500-mg infusion; this regimen should be interpreted as a studied approach rather than a universal schedule. [6] Choose maintenance or retreatment strategies in coordination with pemphigus expertise and according to disease recurrence, prior response, and treatment toxicity. [11]
- Assess new lesion formation and healing at every visit before reducing systemic therapy. [11]
- After rituximab, maintain relapse surveillance because 12-month relapse-free survival has ranged from 40% to 80%. [9]
- A studied rituximab schedule in newly diagnosed disease used 1,000 mg IV on days 0 and 14 followed by 500 mg IV. [6]

*Follow-up decisions after initial PV therapy. [6][9][11]*

| Follow-up finding | Interpretation | Action |
| --- | --- | --- |
| No new lesions and healing erosions | Clinical disease control supports consideration of maintenance and carefully supervised tapering. [11] | Reduce therapy only within a remission-oriented plan rather than by a preset date. [11] |
| New erosions or blisters during taper | Possible relapse or insufficient disease control. [11] | Reassess diagnosis, adherence, disease extent, and need to intensify steroid-sparing therapy. [11] |
| Recurrence after rituximab response | Relapse is expected in a proportion of patients; 12-month relapse-free survival has varied from 40% to 80%. [9] | Reevaluate active disease and formulate retreatment or maintenance strategy with pemphigus expertise. [11][9] |

## Avoid diagnostic and therapeutic errors that prolong exposure to uncontrolled disease

The most consequential errors are misclassification, delayed airway assessment, and unstructured corticosteroid use.

Do not classify every erosive mucosal disorder as PV. Pemphigus variants are distinguished by the level of intraepidermal split formation, while pemphigoid-spectrum disorders blister at the basement membrane zone; biopsy-directed classification should precede long-term immunosuppression. [24][11]

Do not delay laryngeal assessment because oral disease appears mild. PV can involve the larynx, and symptoms suggesting deep laryngeal disease require targeted assessment. [8]

Do not leave patients on prolonged systemic corticosteroid therapy without an explicit steroid-sparing plan when disease severity warrants rituximab or another adjunct. Rituximab's demonstrated steroid-sparing effect and its first-line role in moderate-to-severe disease make early treatment selection clinically important. [4][11]
- Confirm lesion level and immunopathologic pattern before assigning PV subtype. [11][24]
- Treat upper-airway symptoms as a separate assessment problem, not merely an extension of oral pain. [8]
- Plan maintenance and corticosteroid tapering at the time induction therapy is chosen. [11]

*High-impact PV management errors and corrective actions. [4][8][11][24]*

| Error | Why it matters | Correction |
| --- | --- | --- |
| Diagnosing PV from erosions alone | Clinical appearance overlaps with other pemphigus variants and basement-membrane-zone blistering disease. [11][24] | Use lesion-directed histology and immunopathologic testing. [11][24] |
| Ignoring dysphonia or dysphagia | These symptoms may indicate laryngeal involvement. [8] | Arrange direct laryngeal assessment when symptoms are concerning. [8] |
| Continuing corticosteroids without reassessing response | Rituximab can reduce corticosteroid exposure in PV. [4] | Assess disease control and introduce or optimize steroid-sparing treatment for moderate-to-severe disease. [4][11] |

## References
1. Pemphigus - Symptoms, diagnosis and treatment - BMJ Best Practice — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-gb/454
2. Protocol for evaluating the effects of the intelligent multimodal ... — bmjopen.bmj.com — https://bmjopen.bmj.com/content/16/5/e116731.full
3. Treatment of Refractory Pemphigus Vulgaris With Rituximab (Anti ... — jamanetwork.com — https://jamanetwork.com/journals/jamadermatology/fullarticle/480096
4. Optimizing Pemphigus Management With Rituximab and Short-Term ... — jamanetwork.com — https://jamanetwork.com/journals/jamadermatology/fullarticle/2830105
5. Treatment of Pemphigus Vulgaris with Rituximab and Intravenous ... — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMoa062930
6. Factors Associated With Short-term Relapse in Patients With ... — jamanetwork.com — https://jamanetwork.com/journals/jamadermatology/fullarticle/2762874
7. A Single Cycle of Rituximab for the Treatment of Severe Pemphigus — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMoa067752
8. Predicting Laryngeal Involvement in Pemphigus Vulgaris Using a ... — jamanetwork.com — https://jamanetwork.com/journals/jamadermatology/fullarticle/2847174
9. the OBIRINS study protocol, a double-blind randomised controlled trial — bmjopen.bmj.com — https://bmjopen.bmj.com/content/15/12/e111980
10. Mycoplasma pneumoniae–Induced Rash and Mucositis in a 21 ... — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/aimcc.2025.0457
11. Diagnosis and management of pemphigus: Recommendations of an international panel of experts - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S019096221830207X
12. Pemphigus vulgaris and mucous membrane pemphigoid: A systematic review of clinical manifestations, diagnosis, and treatment - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S2468785524002064
13. World Workshop on Oral Medicine VI: a systematic review of the treatment of mucocutaneous pemphigus vulgaris - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S2212440315005672
14. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S019096221000513X
15. Treatment of pemphigus in Australia: Aligning current practises with ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/ajd.13804
16. S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/ddg.14097
17. Pemphigus. S2 Guideline for diagnosis and treatment – guided by ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.12772
18. Oral Pemphigus Vulgaris Treatment with Corticosteroids and ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1155/2022/7583691
19. Efficacy and tolerability of rituximab in patients with pemphigus ... — academic.oup.com — https://academic.oup.com/skinhd/article/6/4/446/8664928
20. Pemphigus vegetans: insights from a systematic review of the literature — academic.oup.com — https://academic.oup.com/ced/article/51/8/1376/8516610
21. Disrupting B and T-cell collaboration in autoimmune disease — academic.oup.com — https://academic.oup.com/cei/article/217/1/15/7655509
22. Trends in Disease Severity and Quality of Life Outcome Measures in ... — academic.oup.com — https://academic.oup.com/skinhd/article/4/5/ski2.429/7896796
23. Interventions for pemphigus vulgaris and pemphigus foliaceus - Martin, LK - 2009 | Cochrane Library — www.cochranelibrary.com — https://www.cochranelibrary.com/en/cdsr/doi/10.1002/14651858.CD006263.pub2/information/en
24. Diagnosis and clinical features of pemphigus vulgaris - PubMed — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pubmed/22560136

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.